Orzeyful Approval for Narcolepsy Type 1 Explained
The FDA approved Orzeyful, or oveporexton, for adults with narcolepsy type 1 as the first approved medicine to directly restore orexin signaling.
Timeline
- August 5, 2026: The FDA announced approval of Orzeyful for adults with narcolepsy type 1.
- After approval: Marketing remained subject to the applicable federal scheduling process described by FDA.
The US Food and Drug Administration approved Orzeyful, the brand name for oveporexton, tablets for adults with narcolepsy type 1 on August 5, 2026. The indication is specific to diagnosed adults; the agency said safety and effectiveness had not been established in patients younger than 18. [1][2]
FDA described Orzeyful as the first approved medicine to treat narcolepsy type 1 as a complete disorder and the first to work by directly restoring orexin signaling. Narcolepsy type 1 involves loss of orexin signaling, which helps regulate wakefulness and related sleep–wake functions. [1]
The approval was supported by two randomized, multicenter, double-blind, placebo-controlled 12-week studies. The prescribing information reports improvements in the ability to stay awake and measures of daytime sleepiness, cataplexy and the broader symptom burden at the studied dose. [1][2]
FDA listed common side effects including insomnia, increased urinary frequency, urinary urgency and increased saliva production. The agency also said Orzeyful should not be used at the same time as strong CYP3A inhibitors. Full contraindications, precautions and dosing belong in the prescribing information. [1][2]
Approval does not mean the drug is appropriate for every person with daytime sleepiness or every form of narcolepsy. Narcolepsy type 1 is a defined condition, and diagnosis, drug interactions, pregnancy considerations and other health factors require evaluation by a qualified clinician. [1][2]
FDA granted the application Breakthrough Therapy designation and Priority Review. Those programs describe the review and development pathway; they are not independent proof that a medicine is risk-free. Patients should use the current label and professional guidance rather than treating an approval headline as personal medical advice. [1][2]
The FDA label describes two morning doses separated by at least three hours, with the second dose no later than 1 p.m., in the studied regimens. A public summary should not convert trial details into individual instructions. Prescribers and patients must use the current approved label because dosing can depend on the marketed formulation and interactions. [2]